What Does G2 Checkpoint Check For: Key Cell Cycle Controls

The G2 checkpoint is a critical control point in the eukaryotic cell cycle that ensures a cell is ready to enter mitosis. It verifies that DNA replication is complete and any DNA damage from the S phase has been repaired. This prevents the division of cells with incomplete or damaged genetic material, which could lead to genomic instability or cell death. If problems are detected, the cell cycle halts to allow for repair or triggers apoptosis if the damage cannot be fixed.

Located at the end of the G2 phase—after DNA synthesis and before mitosis—the G2 checkpoint evaluates three main conditions. First, it confirms that DNA replication is fully completed. Unreplicated DNA can lead to chromosome missegregation during mitosis, resulting in aneuploidy or cell death. The presence of unresolved replication forks activates sensor proteins such as ATR, which initiate a checkpoint response.

Second, the checkpoint screens for DNA damage, including double-strand breaks caused by ionizing radiation or reactive oxygen species. The protein kinase ATM detects these breaks and activates signaling pathways that halt the cycle. ATR responds to replication stress, while both kinases activate downstream effectors like Chk1 and Chk2 Nature.

Third, the cell assesses whether it has sufficient resources—energy and proteins—to support mitosis. While this metabolic check is less emphasized than DNA integrity, it contributes to overall readiness.

The core mechanism involves cyclin B and CDK1, which together form the mitosis-promoting factor (MPF). For mitosis to begin, CDK1 must be activated by the removal of inhibitory phosphate groups via the phosphatase Cdc25. However, when DNA damage is detected, Chk1 and Chk2 phosphorylate Cdc25, leading to its inactivation or degradation. This keeps CDK1 inactive and blocks entry into mitosis.

Once repairs are complete, checkpoint signals fade, Cdc25 becomes active, and CDK1 is dephosphorylated. A feedback loop then rapidly activates more CDK1, creating a switch-like transition into mitosis. This ensures mitosis begins decisively, not partially.

An example of this checkpoint in action occurs when cells are exposed to ionizing radiation. DNA double-strand breaks activate ATM, which triggers phosphorylation of Chk2. This leads to Cdc25 inhibition, CDK1 remains inactive, and the cell arrests in G2. During this pause, repair mechanisms such as homologous recombination fix the damage. Only after repair does the cell resume the cycle and enter mitosis.

Failure of the G2 checkpoint can result in cells dividing with damaged or unreplicated DNA. This leads to chromosomal abnormalities, micronuclei formation, and genomic instability—hallmarks of cancer. Mutations in genes involved in this checkpoint, such as TP53 or ATM, are common in tumors. Cells lacking functional p53 often bypass G2 arrest, increasing mutation accumulation and cancer risk.

In cancer therapy, the G2 checkpoint is a key target. Some treatments, like radiation or certain chemotherapies, cause DNA damage to trigger checkpoint activation and subsequent cell death. However, cancer cells with defective checkpoints may resist these therapies. Conversely, drugs that inhibit checkpoint proteins—such as Chk1 or Wee1—are being studied to force cancer cells with DNA damage into premature mitosis, causing lethal division errors. These strategies exploit inherent weaknesses in tumor cells’ checkpoint controls Khan Academy.

The role of p53 in G2 arrest further influences cell fate. When DNA damage is detected, ATM or ATR activate p53, which functions as a transcription factor. It induces genes like p21, a CDK inhibitor that reinforces G2 arrest by suppressing CDK1-cyclin B activity. If repair succeeds, the cell may continue; if not, p53 can initiate apoptosis through pro-apoptotic genes such as BAX. This dual function helps prevent damaged cells from proliferating.

In contrast, cells without functional p53 often fail to maintain G2 arrest, leading to early mitotic entry. This behavior is common in cancers where TP53 is mutated. These cells depend more on other checkpoint components like Chk1, making them sensitive to targeted inhibitors.

The stringency of the G2 checkpoint also varies by cell type. Embryonic cells and some stem cells often have a less robust G2 checkpoint, allowing faster divisions. In early Xenopus embryos, for instance, G1 and G2 checkpoints are largely absent, enabling rapid cell cycles after fertilization. In contrast, differentiated somatic cells such as fibroblasts enforce strict G2 control and show prolonged arrest after DNA damage. This balance reflects differing priorities between growth speed and genomic fidelity.

Some specialized cells, like mature neurons, exit the cell cycle entirely and no longer divide, making the G2 checkpoint irrelevant in those cells. This context-dependent regulation highlights how checkpoint function aligns with developmental and tissue-specific needs Nature.

Key Takeaways

• The G2 checkpoint ensures DNA replication is complete and DNA damage is repaired before mitosis begins.
• It monitors for unreplicated DNA, DNA breaks, and cellular readiness, using sensor proteins like ATM and ATR.
• CDK1-cyclin B complex activation is blocked by checkpoint kinases (Chk1/Chk2) when damage is detected.
• Failure of the G2 checkpoint can lead to genomic instability and is linked to cancer development.
• Therapeutic strategies aim to manipulate G2 checkpoint controls in cancer cells.
• Always consult a qualified healthcare provider for medical concerns related to cell cycle disorders or cancer.